Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole
Status:
Completed
Trial end date:
2009-03-27
Target enrollment:
Participant gender:
Summary
This will be a single-centre, randomised, double blind, placebo controlled, two-way crossover
study in healthy male and female subjects. There will be two treatment periods each
consisting of 7 days. During each treatment period subjects will receive single doses of
ketoconazole or placebo on the morning of days 1-6 with a single dose of GW642444M on the
morning of Day 5.